Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients

被引:24
作者
Cardoso, Claudia R. L. [1 ]
Signorelli, Flavio V. [1 ]
Papi, Jose A. [1 ]
Salles, Gil F. [1 ]
机构
[1] Univ Fed Rio de Janeiro, Sch Med, Clementino Fraga Filho Univ Hosp, Dept Internal Med, BR-22750240 Rio De Janeiro, Brazil
关键词
antimalarial drugs; dyslipoproteinemias; prevalence; risk factors; SLE disease activity;
D O I
10.1007/s00296-007-0447-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine the prevalence of dyslipoproteinemias and their related factors in a Brazilian systemic lupus erythematosus (SLE) population, fasting lipids were measured in 185 female SLE outpatients. Age, BMI, smoking, post-menopausal status, presence of diabetes and hypertension, SLE duration, number of ARA criteria, drug treatment and disease activity (by SLEDAI) were registered. Statistics included uni and multivariate logistic regression. Eighty-nine patients (48.1%) had hypercholesterolemia, 55 (29.7%) had hypertriglyceridemia and 109 (58.9%) had either. On multivariate analysis, 24-h proteinuria (OR = 2.08, 95% CI: 1.11-3.88), BMI (OR = 1.08, 95% CI: 1.01-1.16) and post-menopausal status (OR = 2.48, 95% CI: 1.25-4.92) were associated with hypercholesterolemia. Disease activity was related to low HDL-cholesterol (OR = 2.59, 95% CI: 1.20-5.58) and, in pre-menopausal patients, also to hypertriglyceridemia (OR = 1.16, 95% CI: 1.03-1.30). Antimalarial use was protective for hypertriglyceridemia (OR = 0.44, 95% CI: 0.22-0.90). In conclusion, the increased prevalence of dyslipoproteinemias is due to proteinuria, obesity and SLE activity. Antimalarials have beneficial effect on lipid profile that may be due to reduction in disease activity.
引用
收藏
页码:323 / 327
页数:5
相关论文
共 22 条
[1]   Significant predictors of poor prognosis in women aged ≤65 years hospitalized for an acute coronary event [J].
Al-Khalili, F ;
Svane, B ;
Janszky, I ;
Rydén, L ;
Orth-Gomér, K ;
Schenck-Gustafsson, K .
JOURNAL OF INTERNAL MEDICINE, 2002, 252 (06) :561-569
[2]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[3]   Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies [J].
Borba, EF ;
Bonfa, E .
LUPUS, 1997, 6 (06) :533-539
[4]  
Bruce IN, 1999, J RHEUMATOL, V26, P2137
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]  
Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO
[7]  
2-I
[8]   Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients [J].
Formiga, F ;
Meco, JF ;
Pinto, X ;
Jacob, J ;
Moga, I ;
Pujol, R .
LUPUS, 2001, 10 (05) :359-363
[9]  
GLADMAN DD, 1987, J RHEUMATOL, V14, P223
[10]  
HODIS HN, 1993, J RHEUMATOL, V20, P661